Small vessel vasculitis and dry gangrene secondary to combined CTLA-4 and PD-1 blockade in malignant mesothelioma
Open Access
- 8 February 2022
- journal article
- case report
- Published by Springer Nature in BMC Rheumatology
- Vol. 6 (1) , 1-5
Abstract
Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive tumour with an overall poor prognosis. In October 2020, first line treatment with the PD-1 antagonist nivolumab and the CTLA-4 antagonist ipilimumab for unresectable disease was FDA approved—the first approved treatment regime since 2004. Interim analyses from the phase 3 CHECKMATE-743 study shows improvements in overall survival. Skin-related toxicities are the most commonly reported any-grade treatment-related adverse event from combined nivolumab and ipilimumab therapy. Case presentation: Here we report a case of a 35-year-old white male who developed digital ischaemia secondary to small vessel vasculitis after receiving PD-1 and CTLA-4 blockade therapy for MPM. His progressive ischaemia became gangrenous, and he required multi-speciality input and treatment with prednisolone, prostacyclin, mycophenolate mofetil and hydroxychloroquine. Conclusions: Our case highlights the importance of early detection, intervention, and a multispecialty approach to managing such complications in order to minimise the associated morbidity and mortality.Keywords
This publication has 12 references indexed in Scilit:
- Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS databaseJournal of Neuro-Oncology, 2021
- Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapyRheumatology, 2019
- Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)Clinical Cancer Research, 2019
- Acral vascular necrosis associated with immune-check point inhibitors: case report with literature reviewBMC Cancer, 2019
- Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trialThe Lancet Respiratory Medicine, 2019
- Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trialThe Lancet Oncology, 2019
- Immune checkpoint inhibitor-related acral vasculitisJournal for ImmunoTherapy of Cancer, 2018
- Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 studyThe Lancet Respiratory Medicine, 2018
- Ipilimumab induced digital vasculitisJournal for ImmunoTherapy of Cancer, 2018
- Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockadeBMC Cancer, 2017